Programmed death ligand-1 expression in non-small cell lung cancer

Keywords

Lung cancerImmunohistochemistryPD-L1Tissue microarrayMedicineOncologyAntibodyCancerIn situ hybridizationMessenger RNAInternal medicinePathologyCancer researchBiologyImmunotherapyImmunologyGene

Affiliated Institutions

Related Publications

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer +27 more

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...

2012 New England Journal of Medicine 12335 citations

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon , Naiyer A. Rizvi , Rina Hui +24 more

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...

2015 New England Journal of Medicine 6054 citations

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Sanjeev Mariathasan , Shannon J. Turley , Dorothee Nickles +39 more

Therapeutic antibodies that block the programmed death-1 (PD-1)–programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancer...

2018 Nature 5078 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Publication Info

Year: 2013
Type: article
Volume: 94
Issue: 1
Pages: 107-116
Citations: 748
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Programmed death ligand-1 expression in non-small cell lung cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

748

OpenAlex

Cite This

APA Style

                            
                                
                                    Vamsidhar Velcheti, 
                                
                                    Kurt A. Schalper, 
                                
                                    Daniel Carvajal
                                
                                et al.
                            
                            (2013). 
                            Programmed death ligand-1 expression in non-small cell lung cancer. 
                            Laboratory Investigation
                            , 94
                            (1)
                            , 107-116.
                            https://doi.org/10.1038/labinvest.2013.130
                        

Identifiers

DOI: 10.1038/labinvest.2013.130